Gyre Therapeutics Q2 revenue $26.8M (+6% YoY); net income falls to $1.6M; CEO transition

GYRE THERAPEUTICS, INC.

2025-Q2 EPS reported $0.01 vs consensus $0.03 ▼ miss (-67.3%)

GAAP net income of $1.6M ($0.00 EPS) vs $4.5M in Q2 2024; H1 net income $5.3M vs $14.5M.
Revenue Q2 $26.8M, up from $25.2M; H1 $48.8M, down from $52.4M due to ETUARY decline and new product launches.
Full-year revenue guidance reaffirmed at $118-128M (11-21% growth). Non-GAAP adj. net income Q2 $2.9M vs $3.1M.
CEO Han Ying resigned, becomes SVP Science; Executive Chair Ping Zhang appointed interim CEO.
Pipeline: Positive Phase 3 Hydronidone data; NDA filing with NMPA expected Q3 2025. Launched Etorel in June.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.